David Goodman‐Meza

ORCID: 0000-0001-9382-3564
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Opioid Use Disorder Treatment
  • HIV, Drug Use, Sexual Risk
  • HIV/AIDS Research and Interventions
  • Sex work and related issues
  • Forensic Toxicology and Drug Analysis
  • Pain Management and Opioid Use
  • Substance Abuse Treatment and Outcomes
  • COVID-19 Clinical Research Studies
  • Infective Endocarditis Diagnosis and Management
  • Orthopedic Infections and Treatments
  • Long-Term Effects of COVID-19
  • Pulmonary Hypertension Research and Treatments
  • SARS-CoV-2 and COVID-19 Research
  • Prenatal Substance Exposure Effects
  • HIV Research and Treatment
  • Emergency and Acute Care Studies
  • Poisoning and overdose treatments
  • Cardiac Imaging and Diagnostics
  • Adolescent Sexual and Reproductive Health
  • Respiratory Support and Mechanisms
  • Heart Failure Treatment and Management
  • Advanced MRI Techniques and Applications
  • COVID-19 diagnosis using AI
  • Hepatitis C virus research
  • Pharmaceutical Quality and Counterfeiting

University of California, Los Angeles
2017-2025

UCLA Health
2020-2025

UNSW Sydney
2024-2025

University of Victoria
2024

RAND Corporation
2024

Public Health Institute
2024

Center for Prevention Services
2024

VA Greater Los Angeles Healthcare System
2019-2024

Veterans Health Administration
2024

Washington University in St. Louis
2021

To describe the trajectory of respiratory failure in COVID-19 and explore factors associated with risk invasive mechanical ventilation (IMV).A retrospective, observational cohort study 112 inpatient adults diagnosed between March 12 April 16, 2020. Data were manually extracted from electronic medical records. Multivariable Univariable regression used to evaluate association baseline characteristics, initial serum markers outcome IMV.Our had median age 61 (IQR 45-74) was 66% male. In-hospital...

10.1371/journal.pone.0238552 article EN public-domain PLoS ONE 2020-12-22

Studies of two SARS-CoV-2 mRNA vaccines suggested that they yield ∼95% protection from symptomatic infection at least short-term, but important clinical questions remain. It is unclear how vaccine-induced antibody levels quantitatively compare to the wide spectrum induced by natural infection. Vaccine response kinetics and magnitudes in persons with prior COVID-19 compared virus-naı̈ve are not well-defined. The relative stability versus infection-induced unclear. We addressed these issues...

10.1021/acsnano.1c03972 article EN ACS Nano 2021-06-23

We retrospectively evaluated the implementation of low-threshold emergency department (ED) buprenorphine treatment at 52 hospitals participating in CA Bridge Program using RE-AIM (reach, effectiveness, adoption, implementation, maintenance) framework.The model included buprenorphine, connection to outpatient care, and harm reduction. Implementation began March 2019. Participating reported aggregated clinical data monthly after program initiation. Outcomes identification opioid use disorder,...

10.1016/j.annemergmed.2021.05.024 article EN cc-by-nc-nd Annals of Emergency Medicine 2021-08-02

Historically, overdose mortality rates among Hispanics have been lower than non-Hispanics. The purpose of this analysis was to characterize the U.S. crisis compared We used Centers for Disease Control and Prevention Wide-Ranging Online Data Epidemiological Research (WONDER) platform obtain drug per 100,000 population between 2010 2021 examined relative percent change specific involvement (2010–2021) state-level disparities (2010–2020) versus calculated rate ratios by state annual in total...

10.1016/j.drugalcdep.2023.109859 article EN cc-by-nc-nd Drug and Alcohol Dependence 2023-03-30

Fentanyl- and methamphetamine-based counterfeit prescription drugs have driven escalating overdose death rates in the US, however their presence Mexico has not been assessed. Our ethnographic team conducted longitudinal research focused on illicit drug markets Northern since 2018. In 2021-2022, study participants described arrival of new, unusually potent tablets sold as ostensibly controlled substances, without a prescription, directly from pharmacies that cater to US tourists.To...

10.1016/j.drugalcdep.2023.110819 article EN cc-by Drug and Alcohol Dependence 2023-06-09

Worldwide, testing capacity for SARS-CoV-2 is limited and bottlenecks in the scale up of polymerase chain reaction (PCR-based exist. Our aim was to develop evaluate a machine learning algorithm diagnose COVID-19 inpatient setting. The based on basic demographic laboratory features serve as screening tool at hospitals where scarce or unavailable. We used retrospectively collected data from UCLA Health System Los Angeles, California. included all emergency room cases receiving PCR who also had...

10.1371/journal.pone.0239474 article EN cc-by PLoS ONE 2020-09-22

Long-acting injectable (LAI) antiretroviral therapy (ART) is a novel HIV treatment option for people with HIV. The first LAI ART regimen received regulatory approval in the United States January 2021. In February 2020, we collected qualitative data from 18 consumers and 23 clinical non-clinical stakeholders to catalog anticipated individual-consumer, healthcare system, structural levels barriers facilitators implementation Los Angeles County, California. Thematic analysis was guided by CFIR...

10.1371/journal.pone.0262926 article EN public-domain PLoS ONE 2022-02-03

Since April 2019, CA Bridge has worked with emergency departments (EDs) in diverse geographic and care settings across California to scale up low-threshold buprenorphine access, patient navigation programs, harm reduction services, take-home naloxone. Between 2019 June 2023, 268 (81.0%) of 331 acute hospitals received funding technical assistance from completed data reporting. These provided services during 279 025 encounters gave patients 89 549 ED visits. (

10.2105/ajph.2024.307710 article EN American Journal of Public Health 2024-06-27

Abstract Background Persons with opioid use disorders who inject drugs (PWID) in the United States (US) face multiple and intertwining health risks. These include interference consistent access, linkage, retention to care including medication for disorder (MOUD), HIV prevention using pre-exposure prophylaxis (PrEP), testing treatment sexually transmitted infections (STIs). Most services, when available, those that address substance misuse, prevention, STIs, are often provided locations may...

10.1186/s13063-023-07899-5 article EN cc-by Trials 2024-02-15

Abstract Background Coccidioidal meningitis (CM) remains a highly morbid condition. Olorofim is novel agent that inhibits the fungal dihydroorotate dehydrogenase enzyme and has potent in vitro activity against Coccidioidomycosis. Demographics of patients at time olorofim initiation with description prior treatments. Methods We performed retrospective case series 4 refractory CM treated between 2020 2024 comparing outcomes assessed by symptoms, brain imaging, Mycosis Study Group (MSG) score....

10.1093/ofid/ofae631.1286 article EN cc-by Open Forum Infectious Diseases 2025-01-29

Background: Substance use disorders (SUD) are a significant public health challenge, necessitating that clinicians trained in SUD treatment and harm reduction (HR) strategies. Despite this, no studies have assessed the extent of HR training across all medical schools. This study assesses current state curriculum among students United States Canada. Methods: From May to July 2023, we conducted an anonymous online survey via email invitation student affairs’ offices 220 accredited US Canadian...

10.1177/29767342251313595 article EN cc-by Substance Use &amp Addiction Journal 2025-02-06

Men who have sex with men (MSM) in developing countries such as Mexico received relatively little research attention. In Tijuana, Mexico, a border city experiencing dynamic HIV epidemic, data on MSM are over decade old. Our aims were to estimate the prevalence and examine correlates of infection among this city. We conducted cross-sectional study 191 recruited through respondent-driven sampling (RDS) 2012. Biological males age 18 resided Tijuana reported male past year included. Participants...

10.7448/ias.18.1.19304 article EN cc-by Journal of the International AIDS Society 2015-01-01

Abstract Background Leronlimab, a monoclonal antibody blocker of C-C chemokine receptor type 5 originally developed to treat human immunodeficiency virus infection, was administered as an open-label compassionate-use therapeutic for coronavirus disease 2019 (COVID-19). Methods Twenty-three hospitalized severe/critical COVID-19 patients received 700 mg leronlimab subcutaneously, repeated after 7 days in 17 23 still hospitalized. Eighteen other experimental treatments, including convalescent...

10.1093/cid/ciaa1583 article EN other-oa Clinical Infectious Diseases 2020-10-15
Coming Soon ...